Table 3.

Endpoints of interest in the Effect of a Vegan versus AHA DiEt in Coronary Artery Disease (EVADE CAD) trial.

Primary Endpoint

High sensitivity C-reactive protein

Secondary Endpoints

Anthropometric data  Weight  Body mass index  Waist circumference  Waist circumference to height ratio

Other markers of inflammation  Myeloperoxidase  White blood cell count  Neutrophil/lymphocyte ratio  Neutrophil-surface expression of L-selectin and the β2 integrin CD11b  Soluble L-selectin and E-selectin  Soluble intercellular adhesion molecule and vascular cell adhesion protein  Soluble neutrophil gelatinase-associated lipocalin  Monocyte subtypes  Oxidized LDL  Urine F2-isoprostane/creatinine

Lipid parameters  Total cholesterol  Low-density lipoprotein (LDL) cholesterol (calculated)  Direct high-density lipoprotein (HDL) cholesterol  Triglycerides  Non-HDL cholesterol  LDL, small LDL, and HDL particle numbers  Large very low-density lipoprotein (VLDL) and large HDL  LDL, VLDL, and HDL size  Lp-PLA2  Lipoprotein insulin resistance index

Glycemic markers  Fasting blood glucose  Blood insulin  Hemoglobin A1c

Other  Index of endothelial function (EndoPAT, Itamar Medical Ltd, Caesarea, Israel)  Quality of life (EuroQol 5 dimensions questionnaire, health evaluation on a visual analogue scale)  Physical Activity (International Physical Activity questionnaire)

Clinical outcomes  Major adverse cardiovascular events (MACE) (a composite of all-cause mortality, non-fatal  myocardial infarction, non-fatal stroke, and repeat coronary revascularization)  Individual components of MACE